High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011
(BUSINESS WIRE)--Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent (Irish Patent Number 60014) expires in November 2011.
“Today’s decision is yet another affirmation of the strength of the intellectual property behind Lipitor,” said Pfizer General Counsel Allen Waxman. “It also is an important outcome for Pfizer and other medical innovators who invest in high-risk research to develop life-saving medicines, and for the patients who benefit from those medicines.”
Pfizer Inc
Bryant Haskins, 212-733-8719